aglatimagene besadenovec,act-903
alpha cancer technologies,candel therapeutics
['sclc', 'can-2409', 'act 903', 'nsclc']
the new frontier: oncolytic viral immunotherapy. a lot of interest at #asco2022 in #candeltherapeutics abstract 9037, showing initial results for #can-2409 in #nsclc. 
Physician-scientist. Immunologist. CEO of Candel Therapeutics ($CADL), focused on development of new immunotherapies for cancer. Views expressed here are my own